Background: TNF inhibitors (TNFi) have been shown to reduce the need for surgery
| BACKGROUND AND HYPOTHESES
Crohn's disease patients eligible for TNF inhibitors (TNFi) represent a group with considerable disease burden who have failed conventional medication such as corticosteroids and thiopurines and therefore are at high risk of surgical intervention. In these patients, biologics have proven efficacious in achieving clinical remission and even complete mucosal healing. [1] [2] [3] [4] [5] While the cost for biological treatment is substantially higher compared to conventional medications, randomised controlled trials (RCT) have demonstrated efficacy in terms of reducing the need for hospitalisation and surgery. [6] [7] [8] [9] However, any sustained long-term benefit with regard to surgery has been difficult to establish since existing randomised trials on the subject are limited to approximately 1 year of duration.
There are a number of 2-to 4-year extension open label studies based on the randomised trials with adalimumab. However, these studies have little focus on the need for surgery and suffer from the same important shortcomings as their underlying RCTs, such as a highly selected patient cohort to optimise the internal validity. [10] [11] [12] [13] In addition to the prospective studies, retrospective observational studies have been published showing a reduced risk of surgery up to 4.6 years (median) after introduction of TNFi in Crohn's disease patients 11, [14] [15] [16] [17] [18] [19] [20] (Table S1 ). However, the majority of these studies are small single centre observations. Indeed, studies with up to 10 years of follow-up of patients with Crohn's disease have failed to convincingly demonstrate decreased surgery rates following the introduction of TNFi. [21] [22] [23] [24] One potential explanation for the lack of efficacy of TNFi in the long term might be gradual loss of response, as is often noticed in clinical routine. 25 The severity of disease often seen in patients treated with biologics is also a confounding factor.
Hence, studies of treatment retention and the risk of bowel resection in unselected, large cohorts of Crohn's disease patients treated with TNFi and cared for in standard medical practice are lacking. We therefore aimed at assessing the need for bowel resection in a patient population with evident sustained benefit of biologics beyond the scope of previous RCTs. 1, 4, 6, 7, 26 In this register-based observational cohort study in Sweden 2006-2014 we compared the rates of first ever bowel resection in patients after start of TNFi in relation to treatment retention, specifically whether patients with treatment retention and who tolerate the drug are less likely to undergo bowel resection than patients who do not respond to or are intolerant to TNFi and therefore taken off the drug before 12 months.
2 | ME TH ODS
| Study design
Using a cohort design, the incidence of first ever bowel resection was compared between patients with sustained response to anti-TNF treatment, defined as remaining on continuous treatment during the first 12 months since start of TNFi, and patients who discontinued treatment within 12 months from initiation of treatment.
| Setting
In Sweden, most patients with IBD are treated by gastroenterolo- Crohn's disease, 556-ulcerative colitis). To increase specificity of the IBD diagnosis, we restricted our study population to patients who had received at least two IBD diagnoses on two separate occasions of which at least one IBD diagnosis was a main diagnosis in the departments of internal medicine, gastroenterology or paediatrics ( Figure 1 ).
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As different IBD diagnoses might be documented during a patient's medical history either due to shift of diagnosis or incorrect registration in the records, we used the two most recent diagnoses prior to start of anti-TNF therapy to classify patients as either Crohn's disease (two ICD-10 codes K50 either as primary or secondary diagnosis) or ulcerative colitis (two ICD-10 codes K51).
If the two most recent diagnoses were not the same, the patient was classified as IBDU, which also included ICD-10 code K52.3.
Hence, the patients were selected based on an IBD diagnosis used as the primary or secondary code entered to the Swedish National Patient Register and afterwards the final diagnosis was based on the last previous two registered IBD diagnoses before first TNFi treatment.
The study population was further restricted to patients with compliance within the first year. 25 We performed sensitivity analyses of bowel resection rates in those patients who discontinued treatment within 6 months.
| Follow-up and occurrence of bowel resection
The outcome measure in this study was bowel resection. Data regarding bowel resection were extracted from the National Patient Register. Surgical procedures were identified using the NOMESCO Classification of Surgical Procedures (Table S5) . 28 Patients were considered at risk of bowel resection from 12 months after first TNFi start and until first of emigration, death or end of follow-up (31 December 2014). We excluded individuals who had developed the outcome of interest before or within 12 months after start of TNFi treatment, or who had less than 6 months of available follow-up time after the first year of anti-TNF treatment ( Figure 1 ).
| Statistics
We calculated crude rates of bowel surgery by dividing the number of first ever bowel resections during follow-up by the corresponding person-time at risk. All rates are presented as number of events per 1000 person-years. To compare the risk of bowel resection in patients who were treated with TNFi for more than or less than 12 months, Cox models were used, stratified by birth year and sex, and adjusted for age at index date. We also calculated stratum-specific hazard ratios (HR) for the calendar period of first Crohn's disease diagnosis, sex, age of first Crohn's disease diagnosis, and phenotype according to the Montreal and Paris classifications. All analyses were performed using The SAS software package, V.9.4 (SAS Institute, Cary, NC, USA).
| RESULTS
We identified 1856 patients with Crohn's disease and without a history of bowel resection before start of their first TNFi treatment ( Figure 1 ). Of these, 1260 (68%) had received adalimumab as first biological and 596 patients (32%) had received infliximab. (Table 1) .
Twelve months after start of anti-TNF treatment 65% of the patients were still on the treatment, 27% had been taken off TNFi, and 7% had undergone early bowel resection during the first 12 months of TNFi treatment and were excluded from further analysis ( Table 1) . Age of IBD onset and duration of IBD before start of biologics affected neither treatment retention nor early bowel resection at 12 months. The proportion of patients with treatment retention ≥12 months or subjected to early bowel resection did not differ by disease location (ileal, colic and ileocolic disease) or by use of additional immunomodulators (Tables 1 and 2) . Treatment retention over time in patients with TNFi ≥12 months is presented in Table S2 .
| 591
| Bowel resection
The cumulative proportion of Crohn's disease patients who had undergone their first bowel resection was 7% (1 year after start of TNFi), 13% (2 years), 17% (3 years), 20% (4 years), 23% (5 years), 25% (6 years) and 28% (7 years) ( Figure 2 ). Compared to patients with treatment retention <12 months, individuals with longer treatment retention had similar bowel resection rates, overall and in stratified analyses ( Figure 2 and Table 2 ). As seen in Table 2 , the only patient factor with significant impact on the risk of bowel resection was start of TNFi treatment <17 years of age.
| Sensitivity analyses
In analyses restricted to Stockholm County with close to full coverage of adalimumab and infliximab, 492 patients with Crohn's disease were included. Adalimumab was prescribed to 255 (52%) and infliximab to 237 patients (48%). We found similar patient characteristics as in the main analyses (Table S3 and Table 1 ) and the risk of early bowel resection and HR for bowel resection after start of follow-up at 12 months ( Figure S1 ) were similar to those of the main analysis ( Figure 2 ).
In post hoc sensitivity analyses, we defined early surgery as <6 months of anti-TNF treatment and compared patients with treatment retention < or ≥ than 6 months respectively ( Figure S2 ). At 6 months, 90% remained on the drug and 4% (n=72) had been subjected to bowel resection. No difference in surgery rates was seen when comparing patients with more or less than 6 months treatment retention as seen in Figure S2 .
4 | DISCUSSION
| Main findings
In this register-based study, we used real world data to describe the association between persistence of TNFi treatment and risk of first ever bowel resection. Overall, the rates of bowel resection during our 6 years of follow-up were similar among patients with TNFi survival <12 months and those with treatment retention ≥12 months. We could not identify any evident predictors (eg, sex, age, duration of disease) for bowel resection. The statistically significant impact of TNFi start <17 years of age is based on a very limited number of patients (n=10) and with an extremely wide confidence interval. The risk for a chance finding is apparent and caution has to be taken when interpreting this result.
| Findings compared to earlier studies
The resection rates after TNFi exposure in this study are similar to the overall risk of abdominal surgery after a first ever diagnosis of
Crohn's disease reported in observational studies: 10%-19% 1 year after diagnosis, 18%-31% after 5 years, and 33%-52% after 10 years (most recent sub-cohort in each study). 21, [35] [36] [37] [38] [39] [40] [41] When interpreting the cumulative frequency of surgical interventions, it should be noted that our patient population was at high risk for surgery due to nonresponse to conventional treatment and thus should show higher frequency of bowel resection compared to the observational studies. The definition (10) 39 (8) 10 (7) 2006-2010 693 (37) 451 (37) 187 (38) 55 (40) 2001-2005 502 (27) 328 (27) 135 (27) 38 (27) 1996-2000 145 (8) 89 (7) 44 (9) 11 (8) 1991-1995 120 (6) 85 (7) 23 (5) 12 (9) 1986-1990 86 (5) 53 (4) 24 (5) 9 (6) 1981-1985 64 (3) 46 (4) 16 (3) 1 (1) 1976-1980 44 (2) 22 (2) 19 (4) 2 (1) 1971-1975 29 (2) 17 (1) 11 (2) vention rate in these RCTs was lower than in this study, for example, 2.2% in the IFX group (ACCENT II) compared to 7% in our study. 2, 6 However, the trials were limited to 54 weeks and carried out according to a strict protocol not allowing concomitant medications or other interventions that are common in clinical practice. The pivotal adalimumab trials also reported beneficial effects on the need for surgery and with longer follow-up compared to the ACCENT studies. 9, 11, 13, 42 Comparison with previous studies is however complicated by the different definitions of surgery. In most RCTs, the definition is limited to Crohn's disease related surgery while we present the frequency of bowel resections (see Table S5 ). Moreover, our aim has been to investigate the risk of surgery in patients na€ ıve to bowel resections while most RCTs also include patients with history of bowel surgery.
An innovative cluster design study by Khanna et al. with 1727 patients engaging 41 community gastroenterology practices randomised to either a top-down approach, ie, early introduction of adalimumab and immunosuppression, or conventional step-up regimen. 19 After 2 years, the early introduction of TNFi resulted in a significant reduction in surgical interventions in the early combined immunosuppression group (6.6%) compared to conventionally treated patients (9.5%) (P=.0314). This patient cohort can be regarded as an approximation of a real-life population, given the cluster design with a large number of community IBD practices. Our reported surgery rate of 13% after 2 years in all patients ever treated with TNFi is considerably higher than in the study by Khanna et al. However, the difference is logical, since 56% of patients in the cluster study were already in clinical remission at inclusion whereas patients in the current cohort were likely treated due to failure of conventional therapy.
A few observational cohort studies with follow-up >2 years have been published regarding TNFi and surgery, ranging from 104 to 614 patients (Table S1 ). Lindsay et al. presented 2-year bowel resection rates of 13.1% which is similar to our results. 18 This study shows an overall major abdominal surgery rate of 23.5% in the IFX-treated patients compared to significantly higher rates among IFX nonresponders (approximately 75%), defined as no benefit after a median of two infusions. The results included fistula-related interventions, which could partly explain the higher frequency of surgery (Table S1 ).
The similar surgical rates between patients with different treatment retention of anti-TNF therapy in our study may have several explanations: (1) The cohort maintained on TNFi for more than 1 year most likely represents patients with the most severe disease.
Without TNF inhibition, the surgical rate would be expected to be higher in this population compared to patients stopping TNFi within 1 year. (2) Our results may also suggest that even though TNFi has a major impact on disease activity and symptom resolution, the effect on the need for surgery in Crohn's disease may be less pronounced in the long run. This raises the question whether TNFi is introduced too late when structural bowel damage is already evident since the mean disease duration to start of TNFi was almost 8 years in our study. An additional issue raised by our results is whether anti-TNF treatment could (in terms of risk of surgery) be safely discontinued after a period of successful treatment. This question is beyond the scope of this study to answer and requires a RCT. Hopefully, the ongoing withdrawal studies might give additional data supporting in this matter. According to the Swedish guidelines, Crohn's disease patients who have failed immune modulating therapy and after initiation of TNFi achieve clinical, biochemical and endoscopic remission may be candidates for stopping TNFi at the earliest after 1 year of treatment. In patients na€ ıve to immunomodulators, TNFi may be stopped before 1 year.
| Limitations
We had limited or no information on disease severity, disease activity or flares and we could therefore not distinguish between patients in stable remission and patients who were still suffering from (Table 2) . However, the lack of influence may be due to the limitations of extrapolating the ICD-codes to the Montreal Classification why this should be taken into account when interpreted.
Another weakness is that we only have information on ADA dispensation and not whether the patient has actually taken the drug. Moreover, we lacked information on the reasons for TNFi cessation (eg, no response, loss of response, side effects etc.). In the current database, we were able to include 100% of ADA-trea- 
| Strengths
This study has many strengths, for instance, a high generalisability.
Our population-based design allowed us to evaluate the effect of TNFi intervention in a nonselected patient population (in contrast, many earlier studies have failed to include uninsured IBD patients;
and RCTs have often only included TNFi responders or patients on stable maintenance therapy). Moreover, the National Patient Register allows for inclusion of all Crohn's disease patients and not only those at highly specialised university and tertiary referral clinics, thereby we minimised selection bias. 28 The size of the study allowed us to calculate more accurate risk estimates, reduces the risk of chance findings and made stratified analyses possible. We also had longer follow-up time than most previous studies, which made it possible to estimate risk of surgery in a longer perspective.
Data quality is high, since clinical information has been collected prospectively through national registers based on routine care and with virtually complete coverage for most variables. It is therefore unsurprising that the validity of both the National Patient Register and the Prescribed Drug Register have been shown to be very high.
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| CONCLUSION S
The risk of bowel resection after start of anti-TNF treatment is higher in regular health care than in published RCTs. Patients on sustained TNFi treatment beyond 12 months have bowel resection rates similar to those who discontinue TNFi treatment earlier.
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